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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S8chemotherapy for ALL according to the Modiﬁed BFM ALL 95 protocol at
our institute, from January 1st 2015 to December 31st 2015. Hyperglyce-
miawas diagnosed with a random blood sugar (RBS) level of200mg/dl or
a fasting blood sugar (FBS) value of 126mg/dl. Patients with pre-existing
diabetes were excluded from analysis.
Results: 165 children with newly diagnosed ALL were analysed of which
eight patients (4.8%) were detected to have hyperglycemia (Range 139 e
646mg/dl). Seven of the patients were females and 50% of them were 10
years of age. No patient had pre-existing diabetes. Five patients (62.5%)
required insulin along with metformin to attain adequate glucose control
while two patients were treated with metformin alone. One of the patients
developed hyperglycemia with an RBS of 264while on treatment for septic
shock and expired shortly after. One child presented with ketoacidosis
associated with blood sugar of 554mg/dl and also had pancreatitis. Two
children had a family history of diabetes mellitus.
Conclusion: The occurrence of hyperglycemia in our study was lower than
previously reported in literature. The incidence of hyperglycemia was
signiﬁcantly increased in female children  10 years of age (p¼0.002).LM-1_V1.6
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Introduction: Acute Lymphoblastic Leukemia is hallmarked by hetero-
geneous characteristics and treatment responsiveness in different sub-
types. Although, the overall cure rate of ALL has improved signiﬁcantly
over the past few decades, cure rates for speciﬁc ALL subgroups vary
signiﬁcantly. Age at diagnosis is identiﬁed as an important prognostic
marker of pediatric ALL. This study aims at analyzing clinical, hemato-
logical, biochemical, immunophenotypical parameters and treatment
responsiveness in children upto two years of age, who are diagnosed with
ALL.
Materials & methods: It is a retrospective data analysis conducted at a
Tertiary Care Cancer Centre in South India. The study population includes
all Pediatric ALL upto 2 years of age, registered at this institute during
January 2009 to December 2013. The details included in the study were
collected from case records, hospital cancer registry and during follow up
and percentages were calculated for the variables using appropriate sta-
tistical tools.
Results: The total number of pediatric malignancies registered during the
period were 2640, out of which 422 cases were under 2 years of age with
ALL contributing 122 cases (29%).Among them, 48 children refused treat-
ment due to various reasons and four were lost to follow up. Thus, 70
children are eligible for analysis.
Among 70 children, infants were 13 (18%) and the remaining 57 children
(82%) were in the 1-2 years group. There were 39 males (56%) and 31 fe-
males (44%), the ratio being 1.25:1. Fever was present in 62 children (88%),
and pallor in 57 (81%). Hepatosplenomegaly was observed in 59 children
(84%) and isolated hepatomegaly in 9 (14%). Lymphadenopathy was noted
in 52 (74%).Bleeding manifestations were present in 9 (11.5%) and paroti-
domegaly in 3 (4.25%).
Hemogram revealed hemoglobin <7gm/dL in 25 children (35%), 7-11 gm/
dL in 35 (50%) and >11 in 10 (15%).Initial WBC count was < 10,000 in 25
children (36%), another 36% had counts between 10,000- 49,000 and the
remaining 20 (28%) hadmore than 50000.Platelet count was <20,000 in 14
children (20%), 20,000-99,000 in 51 (74%) and >1 lakh in 6%.
Serum LDH was elevated (>250 IU) in 45 children (64%) and Uric acid in 8
(11.5%).Renomegaly was detected by ultrasound in 12 (17%).Only one child
had CNS 3 disease.L1morphologywas seen in 66 children (94%) and L2 in 4
(6%). Immunophenotype was done in 44 children, 41 (93%) were Precursor
B ALL and 3 (7%) Precursor T ALL.
Event Free Survival was 63%. Among 26 children who succumbed (37%),
three died before the commencement of chemotherapy (4.3%), 6 childrendied during induction (8.5%) and 17 (24.2%) died after relapse. Four out of
11 infants (36%) and 40 among 1-2 years group (70%) survived.
Conclusion: Commonest clinical features were fever, hepatosplenomegaly
and pallor. Predominant morphology was L1 and immunophenotype,
Precursor B ALL. Treatment of infantile ALL is a challenge and is associated
with signiﬁcantly lower survival as compared to 1-2 years group.
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Purpose: To evaluate treatment response, patterns of failure and prog-
nostic factors for patients with NLPHL treated at the Tata Memorial Hos-
pital (TMH).
Materials and Methods: Between January 2008 & July 2013, 62 patients
with histologically proven NLPHL in the age group of 6-70yrs (Median
30.6Yrs) were treated at TMH. Forty ﬁve (73%) were males. Majority had
Stage I (48%) & Stage II (24%) disease. Fifteen (24%) had bulky disease at
presentation. Sixteen (26%) were treated with Involved Field Radiation
Therapy (IFRT) alone, 18 (29%) received Chemotherapy (CTh) alone, while
23 (39%) received a combination of CTh followed by IFRT. Five patients
underwent surgery as the local treatment. The IFRT doses were in the
range of 20-36 Gy. Thirty-four (80%) patients received ABVD CTh. Five (8%)
patients received Rituximab. Primary MINE CTh was used for 4 (6%)
patients.
Results: After a median follow-up of 18 months, the 2 year disease free
survival (DFS) and overall survival (OS) were 86% and 98% respectively.
Complete response (CR) at completion of primary treatment was 94%. At
last follow up 55 (89%) were alive without disease. Two (3%) patients each
had in-ﬁeld, out of ﬁeld and disseminated relapse. Four (6%) had residual
disease and one (2%) had transformation to DLBCL. Six (55%) patients
received salvage treatment (3 IFRT, 3 CTh), of which 4 were disease free at
last FU. On univariate analysis, early stage, absence of B symptoms and use
of IFRT resulted in superior DFS. For patients with early stage disease (stage
I and II), there was no difference in DFS (94%) between patients receiving
IFRT alone and CTh + IFRT. The use of IFRT was associated with improved
DFS (91% vs. 78%, p¼0.57). All patients tolerated treatment well without
any grade III or IV toxicities.
Conclusion: NLPHL is associated with excellent overall survival. For pa-
tients with early stage disease, IFRT alone results in similar outcomes
compared to CTh+IFRT. Early Stage at presentation, absence of B symptoms
and the use of IFRT confers superior outcome.
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Introduction: Ph +ve ALL is a very high-risk subset of childhood ALL with
historically poor outcomes without stem cell transplantation (SCT) before
the advent and use of Imatinib Mesylate. The incidence of Ph +ve ALL at our
centre is higher at 7% as compared to 2-3% in the west. There is a paucity of
data on the clinical presentation outcomes of Ph+ve ALL in India, where
SCT is not affordable for most patients.
Aim: We conducted a retrospective analysis of paediatric Ph +ve ALL pa-
tients treated with intensive chemotherapy with or without Imatinib.
